Genvor’s Peptides Head to USDA Sugar Beet Trial

Dr. Jesse Jaynes, the company’s co-founder and the scientist behind its core peptide technology, said the collaboration lets Genvor test its peptides against a new set of microbial targets. The work, he added, continues the design improvements that make the tools more effective.

The research is expected to generate data that could inform future peptide-based strategies for crop protection and post-harvest quality. Genvor is still early stage – the company has no commercial sales from this program – but the USDA collaboration gives its technology a real-world testing venue with a federal agency that has deep agronomy expertise.

Genvor’s platform, BioCypher, generates novel peptides using AI. The company is also developing products for human health and wellness, but the agricultural pipeline is where the near-term milestones sit. Sugar beet is a high-value crop in the U.S. and Europe, and microbial losses during storage and processing represent a meaningful cost to the industry. Any peptide-based solution that reduces those losses could command premium pricing over conventional chemical treatments.

The collaboration does not include a disclosed budget, timeline, or revenue-sharing arrangement. Genvor’s stock trades on the OTCQB under GNVR. The shares were inactive Monday following the announcement.